2019
-
Lung Cancer Global Mortality Projections Skyrocket for Women
By Joy Curzio Posted: April 1, 2019 Lung cancer is the leading cause of cancer death among women, with the 5-year survival rate at just 21%.1 An estimated 70,500 women in […]
-
Mentorship and Travel Awards for Nursing and Allied Health at WCLC 2018
By Erik MacLaren, PhD Posted: April 1, 2019 In September 2018, several attendees of the 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada, received Travel and Mentorship Awards from […]
-
Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung Cancer
By Michael MacManus, MD, FRANZCR, and Tim Akhurst, MD, FRACP Posted: March 1, 2019 Dr. Michael MacManus 18F-FDG PET/CT scans portray living biology and are indispensable in thoracic oncologic evaluations, […]
-
Lung Cancer Pathology Pioneer Dr. Adi Gazdar Dies at 81
Posted: March 1, 2019 Adi Gazdar, MD, a true giant in the field of lung cancer research, passed away on December 29, 2018. Dr. Gazdar was the W. Ray Wallace […]
-
Uncommon Oncogenic Drivers in NSCLC
By Karen L. Reckamp, MD, MS Posted: March 1, 2019 Dr. Karen L. Reckamp Identification of genetic alterations in NSCLC has transformed diagnosis and treatment for patients with advanced disease. […]
-
The Changing the Landscape of Tobacco Products: Potential Effects of ENDS and HTPs
By Carolyn M. Dresler, MD, MPA Posted: March 1, 2019 It is common knowledge that the number one cause of preventable deaths in the world is from tobacco use—overwhelmingly from […]
-
Diagnostic Oncology: Reports from the IASLC Pathology Committee
By Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE Posted: March 1, 2019 There was a time, remembered by us older pathologists, when the image of pathology was that of a […]
-
Improving Clinical Trials Through Clinician, Patient Use of Social Media
By DR CamidgePosted: March 1, 2019 The National Cancer Institute featured a workshop in June 2018 titled “At the Crossroads of Social Media and Clinical Trials: A Workshop on the […]
-
IMpower133: Finally Moving the Needle in SCLC
By Stephen V. Liu, MD Posted: March 1, 2019 Dr. Stephen V. Liu The addition of atezolizumab to standard chemotherapy for extensive-stage SCLC achieved what, for decades, had been beyond […]
-
Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for NSCLC
Posted: March 1, 2019 In the following interview, Jamie E. Chaft, MD, a medical oncologist at the Memorial Sloan Kettering Cancer Center, discusses new data on induction immunotherapy for patients […]
View ILCN Archives
Provider Resources